Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
295.08B
Market cap295.08B
Price-Earnings ratio
16.82
Price-Earnings ratio16.82
Dividend yield
2.68%
Dividend yield2.68%
Average volume
9.91M
Average volume9.91M
High today
$122.80
High today$122.80
Low today
$119.00
Low today$119.00
Open price
$122.45
Open price$122.45
Volume
10.31M
Volume10.31M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 295.08B, Merck(MRK) trades at $119.30. The stock has a price-to-earnings ratio of 16.82 and currently yields dividends of 2.7%.

As of 2026-02-26, Merck(MRK) stock has fluctuated between $119.00 and $122.80. The current price stands at $119.30, placing the stock +0.3% above today's low and -2.9% off the high.

The Merck(MRK)'s current trading volume is 10.31M, compared to an average daily volume of 9.91M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $73.31.

MRK News

24/7 Wall St. 7h
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet

Merck Stock Jumps But Reddit Traders Are Getting Cold Feet Quick Read Merck (MRK) faces a December 2028 patent expiration for Keytruda. The drug generates roug...

Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
Simply Wall St 21h
Merck Valuation Check As Keytruda Patent Risk Drives Major Human Health Restructuring

Advertisement Keytruda patent risk puts Merck (MRK) restructuring in focus Merck (MRK) is splitting its human health business into two units, Oncology and Spe...

Merck Valuation Check As Keytruda Patent Risk Drives Major Human Health Restructuring
TipRanks 1d
Merck Animal Health says FDA approves Numelvi for Dogs

Merck (MRK) Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck, announced the U.S. Food and Drug Administrat...

Analyst ratings

61%

of 31 ratings
Buy
61.3%
Hold
38.7%
Sell
0%

More MRK News

Barron's 1d
Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Biotech and Pharma Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. In this article MRK GILD Merck said its e...

Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
Simply Wall St 2d
Merck Reorganizes Human Health To Shape Life After Keytruda

Merck (NYSE:MRK) is restructuring its Human Health division into two units: Oncology and Specialty, Pharma & Infectious Diseases. The company has announced new...

Merck Reorganizes Human Health To Shape Life After Keytruda
TipRanks 2d
Merck initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Merck (MRK) with an Outperform rating and $142 price target The firm sees the stock’s investor enthusiasm continuing with near...

Benzinga 2d
Amazon, Merck, PG&E And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, named Amazon.com, Inc. (NASDAQ:AMZN) as...

Amazon, Merck, PG&E And More On CNBC's 'Final Trades'
Simply Wall St 3d
Merck Restructures Human Health To Highlight Oncology And Post Keytruda Growth

Merck (NYSE:MRK) plans to split its Human Health business into two divisions: one for oncology and one for specialty, pharma, and infectious diseases. The rest...

Merck Restructures Human Health To Highlight Oncology And Post Keytruda Growth
Benzinga 3d
Merck's Strategic Shift Signals New Growth Horizons

Merck & Co. Inc. (NYSE:MRK) shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execu...

Merck's Strategic Shift Signals New Growth Horizons
Barron's 4d
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Feature Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. In this article MRK SNY Merck’s blockbuster cancer treatment Keytruda...

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.